Diseased small blood vessels in the brain cause about a quarter of all strokes and are the main driver of vascular dementia. Despite this, doctors have few treatments because the underlying disease processes remain poorly understood. This project uses two advanced brain imaging techniques to test whether a leaky blood-brain barrier and brain inflammation are actively driving the disease forward. In pilot studies, the team has already detected both abnormalities in patients with cerebral small vessel disease (SVD). They will now scan a larger group to see whether patients with more leakage or inflammation experience faster disease progression. In the final stage, they will give patients a drug called minocycline—already used for other conditions—to see if it can “switch off” both the leakiness and the inflammation, as it does in animal models. If the drug works, it would open a completely new avenue for treating a disease that currently has few options. Even if minocycline fails, proving that these processes are central to SVD would give drug developers clear targets to aim at, potentially slowing the dementia and stroke burden in an ageing population.
View original technical description
Disease of the small blood vessels within the brain (cerebral small vessel disease - or SVD) causes about a quarter of all strokes and is the main cause of vascular dementia. Its impact in causing dementia is even greater because many case of dementia particularly in the elderly are caused by a combination of stroke-like disease (primarily SVD) with diseases such as Alzheimer's. Therefore it presents a major public health problem which will only increase as the population ages. Despite its importance there are few treatments for SVD. A major problem in developing new treatments is that we don't fully understand what causes the disease and what makes it progress. Recent data has suggested two new processes may be important. One of these is leakiness of the blood brain barrier (BBB) which separates the blood vessels from the brain tissue. The second is inflammation within the brain. It is now possible to image both of these processes in patients with SVD and this is allowing us, for the first time, to determine how important these processes are in the disease. In pilot studies we have shown we can detect abnormalities in patients with SVD using these brain imaging techniques. We will now apply these techniques in more detail in this project. We will use an MRI technique in which one gives injection of a contrast agent (gadolinium) to look at leakiness of the BBB in patients with SVD. We will determine how common this leakiness is and whether patients with more leakiness have disease which progresses faster. Secondly we will use another imaging technique called positron emission tomography (PET) to image inflammation within the brain. We will determine whether BBB leakiness relates to inflammation and whether both these processes are associated with more rapid disease progression. In the final part of the project we will determine whether we can "switch off" BBB leakiness and inflammation by giving a drug called minocycline. This drug is widely used for other purposes and has been shown to switch off these both BBB leakiness and inflammation in an animal model of SVD. If we can show that these processes are important in SVD in man, and can be switched off by drugs, this will open up a completely new avenue in treatment of this important disease in man.
Daniel Tozer (Co-Investigator)Franklin Aigbirhio (Co-Investigator)Guy Williams (Co-Investigator)Hugh Markus (Principal Investigator)John O'Brien (Co-Investigator)Tim Fryer (Co-Investigator)
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know